Search for: "FTC v. Watson Pharmaceuticals, Inc., et al."
Results 1 - 13
of 13
Sorted by Relevance
|
Sort by Date
FTC and California AG Join in Challenging Reverse Payment Settlements in the Pharmaceutical Industry
6 Mar 2009, 7:03 am
Trade Comm'n et al. v. [read post]
24 Jun 2013, 6:08 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
24 Jun 2013, 10:08 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
25 Jun 2013, 9:51 am
Watson Pharmaceuticals, Inc. [5] Citing FTC v. [read post]
6 Oct 2010, 4:22 am
Sandoz, Inc. et al (Docket Report) [read post]
27 Apr 2010, 10:58 pm
Orthofix International N.V. et al. [read post]
29 Aug 2022, 9:05 pm
Still, the FTC and DOJ do not appear deterred. [read post]
3 Mar 2010, 5:05 am
Assistance Publique - Hopitaux De Paris et al. [read post]
3 Mar 2010, 5:05 am
Assistance Publique - Hopitaux De Paris et al. [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]
8 Feb 2008, 7:00 pm
– Facebook’s contractual rights to users’ photos problematic: (Spicy IP)PharmaEuropean Commission probes pharmaceutical sector: (Philip Brooks),WHO Board sets course on IP, avian flu, tighter publication policy: (Intellectual Property Watch),India: The Competition Act, patents and over hyped drugs: (Part I - Spicy IP), (Part II – Spicy IP), (Part III – Spicy IP),Ignoring not the solution … [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
18 May 2009, 5:24 am
: Omnicare, Inc v OHIM, Astellas Pharma GmbH (Class 46) CFI delivers judgment in case concerning ability of designer who assigns business and related IP to another company, to object when the company tries to register his name as a CTM: Elio Fiorucci v OHIM (IPKat) CFI: Good faith irrelevant when selling non-misleading sausages: Alberto Severi, in his own name and representing Cavazzuti e figli SpA, now known as Grandi Salumifici Italiani SpA v Regione… [read post]
